Immunotherapy for the Treatment of Head and Neck Cancers: Module 6 of 12

REGISTER HERE
aci17-sitc-clr.jpg

It is important to note there are twelve ACI online modules, you are currently reviewing module six. You may complete any of the modules in the order you choose. Each module can be completed independently for continuing education credit. 


The Immunotherapy for the Treatment of Head and Neck Cancers module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of head and neck cancers. The module also includes case studies on immunotherapy for the treatment of head and neck cancers.


Module 6
Joshua Bauml, MD – University of Pennsylvania

Educational Objectives 

  • Discuss clinical trials that are underway to improve immunotherapy response rates
  • Describe patient case studies with fewer side effects on PD-1 Abs than chemotherapy
  • Outline clinical data on the efficacy and mechanism of action of approved therapies
  • Recognize patient selection criteria for approved therapies
  • Select appropriate dosing and sequencing of approved therapies

Target Audience

The ACI 2017 video series have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

Related Class Content

All modules offer Continuing Education (CE) Credit

Register/Access Class

Target Audience
Clinician Icon

Credit Available
Oct. 6, 2017- Sept. 30, 2018

Credits
  • CME: 0.5 AMA PRA Category 1 Credit(s)™
  • CNE: 0.5 contact hours, with 0.2 pharmacotherapy contact hours
  • CPE: 0.5 contact hours (0.05 CEUs)

Approximate Time to Complete
0.5 hours

Cost
Free

Please use one of the following Internet browsers to open this activity: Chrome, Firefox, or Safari browsers in order to view this online activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer 

The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from 
Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.